ClinicalTrials.gg
TerminatedNCT05846659Updated May 15, 2026Results posted

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

A Phase 2 interventional study of IMSA101 and Immune checkpoint inhibitor in Oligoprogressive, sponsored by ImmuneSensor Therapeutics Inc.. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by ImmuneSensor Therapeutics Inc. · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Why this study was terminated
Change in ImmuneSensor corporate strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.

Read the detailed description

Patients shall be enrolled in 2 treatment arms as follows:

  1. 15 patients in the control arm (PULSAR-ICI alone)
  2. 30 patients in the experimental arm (PULSAR-ICI + IMSA101)

PULSAR-ICI with or without IMSA101 treatment will be administered to the patients in Cycles 1, 2, and 3, and thereafter only standard of care ICI monotherapy will be administered to all patients. Each treatment cycle will be 28 days in duration for Cycles 1, 2 and 3, then per standard of care monotherapy thereafter based on the product labels of the prescribed ICI.

The study will start with a safety run-in portion at 2 dose levels for the experimental arm, followed by a randomized portion for both treatment arms. The safety run-in shall employ a 3+3 safety run-in component.

All patients will be followed throughout the study for drug tolerability and safety by collecting clinical and laboratory data, including adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria, SAEs, concomitant medications, and vital signs.

All patients will be assessed for anti-tumor efficacy at screening, prior to the end of Cycle 3, and at 8-week intervals thereafter based on radiographic assessments (all outcome measures per RECIST Version 1.1 and iRECIST).

Tumor types and the corresponding treatment combinations to be evaluated will be identified prior to the first patient enrolled.

All patients will continue to receive their assigned treatment throughout the study until the occurrence of disease progression (based on iRECIST), death, or other unacceptable treatment-related toxicity, or until the study is closed by the sponsor.

02

Conditions studied

  • Oligoprogressive

Keywords

  • Oligoprogressive solid tumor malignancies
  • Adult
03

In context

Lead sponsor

ImmuneSensor Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years of age
  2. Signed and mental capability to understand the informed consent
  3. or cytologically documented solid tumor demonstrating new progression through prior anti-cancer therapy, with a prior 2 months of clinical stability (with at least Stable Disease), with radiographically documented presence of ≤ 6 lesions consistent with the diagnosis of "oligoprogressive" disease that are technically amenable to PULSAR
  4. Patient's disease must be evaluable per Version 1.1
  5. All metastatic lesions amenable to administration of radiotherapy, at the discretion of the investigator
  6. Must have at least one single pre-defined progressing lesion/lesion site (longest diameter ≥ 10 mm and ≤ 50 mm) suitable for intra-tumoral injection
  7. (ECOG) performance status of ≤ 1
  8. (ECG) without evidence of conduction abnormalities or active ischemia as determined by the investigator
  9. Acceptable organ and marrow function as defined below:

    • (ANC) > 1,500 cells/μL
    • > 50,000 cells/μL
    • Total ≤ 1.5 times (×) the (ULN)
    • (AST)/alanine aminotransaminase (ALT) ≤ 2.5 × ULN. If liver metastases are present, AST/ALT \< 5 × ULN
    • Serum creatinine \< 1.5 mg/dL and a measured ≥ 50 mL/min using the Cockcroft-Gault formula
    • (PT)/partial thromboplastin time (PTT) ≤ 1.5 × ULN
  10. Women of (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization [hysterectomy, bilateral salpingectomy, or bilateral oophorectomy]) or is not (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, eg, greater than 45 years) must have a negative serum pregnancy test prior to first dose of study treatment
  11. Male and female patients with must agree to use two forms of highly effective throughout the study

Exclusion criteria

Exclusion Criteria:

  1. Prior receipt of stimulator of interferon genes (STING) agonist
  2. Prior receipt of therapeutic radiotherapy to all progressive lesions intended for PULSAR treatment
  3. Anti-cancer therapy, except pembrolizumab and nivolumab, within 4 weeks or \< 5 half-lives of the first dose of study treatment
  4. Existence of primary tumor that requires therapeutic treatment beyond the provided drug
  5. Failure to recover, to Grade 1 or less, from AEs due to prior anti-cancer therapy, as judged by the investigator
  6. Previous life-threatening (Grade 4) immune-related adverse event (irAE)
  7. Known untreated or treated brain metastases that have not been stable (scan showing no worsening of central nervous system [CNS] lesion[s] and no requirement of ) ≥ 4 weeks prior to study enrollment
  8. Existence of actionable mutations that are eligible for a mutation-targeting drug that represents standard-of-care
  9. Baseline prolongation of /corrected QT (QTc) interval (QTc interval > 470)
  10. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in the opinion of the investigator would limit compliance with study requirements
  11. Women who are pregnant or breastfeeding
  12. Sponsor reserves the right to exclude any patient from the study on the basis of pre-study medical histories, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    PULSAR-ICI + IMSA101

    Drug: IMSA101 · Drug: Immune checkpoint inhibitor · Radiation: PULSAR

  • Active comparator
    Control Arm

    PULSAR-ICI

    Drug: Immune checkpoint inhibitor · Radiation: PULSAR

Interventions

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Anti-tumor Effects

    Progression-free rate at 12 months

    Time frame: 12 months

Secondary outcomes

  1. Safety and Tolerability

    Occurrence of treatment-related adverse events and SAEs

    Time frame: 8 months

  2. Anti-tumor Effects

    Progression-free at 8-week intervals from 6 months to 8 months.

    Time frame: 6 to 8 months

  3. Anti-tumor Effects

    Time-to-progression (TTP)

    Time frame: upon enrolment through end of study period (8 months)

  4. Anti-tumor Effects

    Overall response rate, duration of response, progression-free survival

    Time frame: upon enrolment through end of study period (8 months)

  5. Functional Assessment of Cancer Therapy - General (FACT-G) Quality of Life (QoL)

    The Functional Assessment of Cancer Therapy - General (FACT-G) is a patient-reported outcome (PRO) assessing health-related quality of life (HRQoL) in individuals with cancer across physical, social/family, emotional, and functional domains. The FACT-G (Version 4) contains 27 items across four subscales. Each item uses a 0-4 Likert scale (0 = Not at all, 4 = Very much), with some items reverse-scored so that higher scores always indicate better quality of life. Physical Well-Being (PWB) - 7 items, score range 0-28 (higher = better physical well-being. Social/Family Well-Being (SWB) - 7 items, score range 0-28 (higher = better social/family well being) Emotional Well-Being (EWB) - 6 items, score range 0-24 (higher = better emotional well-being) Functional Well-Being (FWB) - 7 items, score range 0-28 (higher = better functional well being) Scores provided show average baseline and average post-baseline comparison scores for all patient who completed the FACT-G questionnaire on trial

    Time frame: upon enrolment through end of study period (8 months)

07

Results

Posted May 15, 2026

Participant flow

Study was terminated early by sponsor due to change in corporate strategy.

Participant flow — Overall Study
MilestoneExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Started3112
Completed000
Not completed3112
Withdrew: Withdrawal by subject110
Withdrew: Lack of efficacy130
Withdrew: Early study termination172

Outcome measures

PrimaryAnti-tumor Effects

Progression-free rate at 12 months

Time frame:
12 months
Reported as:
Count of participants · Participants
Anti-tumor Effects
ParticipantsExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Anti-tumor Effects000
SecondarySafety and Tolerability

Occurrence of treatment-related adverse events and SAEs

Time frame:
8 months
Reported as:
Count of participants · Participants
Safety and Tolerability
ParticipantsExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Safety and Tolerability3112
SecondaryAnti-tumor Effects

Progression-free at 8-week intervals from 6 months to 8 months.

Time frame:
6 to 8 months
Reported as:
Count of participants · Participants
Anti-tumor Effects
ParticipantsExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Progression Free100
Not evaluable100
SecondaryAnti-tumor Effects

Time-to-progression (TTP)

Time frame:
upon enrolment through end of study period (8 months)
Reported as:
Count of participants · Participants
Anti-tumor Effects
ParticipantsExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Progressed in 5 months100
Progressed in 4 months010
Not evaluable2102
SecondaryAnti-tumor Effects

Overall response rate, duration of response, progression-free survival

Time frame:
upon enrolment through end of study period (8 months)
Reported as:
Count of participants · Participants
Anti-tumor Effects
ParticipantsExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Complete Response000
Partial Response100
Stable Disease000
Progressive Disease110
Not evaluable1102
SecondaryFunctional Assessment of Cancer Therapy - General (FACT-G) Quality of Life (QoL)

The Functional Assessment of Cancer Therapy - General (FACT-G) is a patient-reported outcome (PRO) assessing health-related quality of life (HRQoL) in individuals with cancer across physical, social/family, emotional, and functional domains. The FACT-G (Version 4) contains 27 items across four subscales. Each item uses a 0-4 Likert scale (0 = Not at all, 4 = Very much), with some items reverse-scored so that higher scores always indicate better quality of life. Physical Well-Being (PWB) - 7 items, score range 0-28 (higher = better physical well-being. Social/Family Well-Being (SWB) - 7 items, score range 0-28 (higher = better social/family well being) Emotional Well-Being (EWB) - 6 items, score range 0-24 (higher = better emotional well-being) Functional Well-Being (FWB) - 7 items, score range 0-28 (higher = better functional well being) Scores provided show average baseline and average post-baseline comparison scores for all patient who completed the FACT-G questionnaire on trial

Time frame:
upon enrolment through end of study period (8 months)
Reported as:
Mean · Scores on a scale
Functional Assessment of Cancer Therapy - General (FACT-G) Quality of Life (QoL)
Scores on a scaleExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Physical Well Being - Baseline.95 ± .85.79 ± .41.71 ± .95
Physical Well Being - post-Baseline.98 ± .431.08 ± .44—
SOCIAL/FAMILY WELL-BEING - Baseline3.14 ± 1.442.84 ± 1.343.0 ± 1.73
SOCIAL/FAMILY WELL-BEING - Post Baseline2.96 ± 1.232.81 ± 1.31—
EMOTIONAL WELL-BEING - Baseline1.13 ± 1.141.15 ± 1.141.32 ± .82
EMOTIONAL WELL-BEING - Post Baseline1.10 ± 1.011.27 ± .79—
FUNCTIONAL WELL-BEING - Baseline2.88 ± .442.87 ± .213.29 ± .76
FUNCTIONAL WELL-BEING - Post baseline2.93 ± .532.25 ± .47—

Adverse events

Collected over 8 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm (800 mcg)0/3 (0%)1/3 (33.3%)3/3 (100%)
Experimental Arm (1200 mcg)0/11 (0%)2/11 (18.2%)11/11 (100%)
Control Arm0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
Flank PainMusculoskeletal and connective tissue disorders1/30/110/2
Cerebrovascular accidentNervous system disorders1/30/110/2
Injection Site ReactionGeneral disorders0/31/110/2
Hip FractureMusculoskeletal and connective tissue disorders0/31/110/2
Most frequent other events
Showing 10 of 20
Most frequent other events
EventExperimental Arm (800 mcg)Experimental Arm (1200 mcg)Control Arm
DyspnoeaRespiratory, thoracic and mediastinal disorders2/31/110/2
NauseaGastrointestinal disorders1/36/110/2
Blood alkaline phosphatase increasedInvestigations1/31/111/2
Blood creatinine increasedInvestigations1/30/111/2
Blood lactate dehydrogenase decreasedInvestigations0/31/111/2
VomitingGastrointestinal disorders1/35/110/2
FatigueGeneral disorders1/34/110/2
PyrexiaGeneral disorders1/34/110/2
AnaemiaBlood and lymphatic system disorders1/33/110/2
ChillsGeneral disorders1/31/110/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental Arm (800 mcg)Experimental Arm (1200 mcg)Control ArmTotal
<=18 years0000
Between 18 and 65 years1618
>=65 years2518
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm (800 mcg)Experimental Arm (1200 mcg)Control ArmTotal
Female1517
Male2619
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental Arm (800 mcg)Experimental Arm (1200 mcg)Control ArmTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White29213
More than one race0000
Unknown or Not Reported0101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental Arm (800 mcg)Experimental Arm (1200 mcg)Control ArmTotal
Hispanic or Latino1203
Not Hispanic or Latino29213
Unknown or Not Reported0000
08

Study locations

14 sites
  • City of Hope Orange County Lennar Foundation Cancer Center
    Irvine, California 92618, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Brigham and Women's Hospital/Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
    New York, New York 10016, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Louis Stokes Cleveland VA Medical Center
    Cleveland, Ohio 44106, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine Medical Center
    Houston, Texas 77030, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Nov 2024, 16 months.

Results were first posted in May 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 6, 2023
StartActual
Jul 7, 2023
Primary completionActual
Nov 20, 2024
CompletionActual
Nov 20, 2024
Results first posted
May 15, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05846659
Lead sponsor
ImmuneSensor Therapeutics Inc.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jul 7, 2023
Primary completion
Nov 20, 2024
Completion
Nov 20, 2024
Results posted
May 15, 2026
Last update
May 15, 2026

Study contacts

Patrick Widhelm
study director · ImmuneSensor Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STING Agonist IMSA101

Start the discussion